Findings from a literature review indicate that overall costs of long-acting insulin analogues are not significantly different from those of intermediate-acting human insulin and oral antidiabetic agents.
Berhanu Alemayehu, DrPH, MS
Advertisement
Articles by Berhanu Alemayehu, DrPH, MS
Advertisement
Latest Updated Articles
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender AdultsPublished: August 18th 2025 | Updated: August 25th 2025
Semaglutide Not Associated With Increased Risk of Eye DisordersPublished: August 19th 2025 | Updated: August 22nd 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?Published: June 6th 2025 | Updated: August 18th 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health SystemPublished: June 27th 2025 | Updated: July 1st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPPPublished: February 20th 2025 | Updated: February 21st 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC CasesPublished: January 16th 2025 | Updated: January 29th 2025
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5
